New sickle cell drug passes heart safety check in healthy volunteers
NCT ID NCT07023029
First seen Oct 31, 2025 · Last updated Jun 13, 2026 · Updated 35 times
Summary
This study tested whether a new medicine called etavopivat, being developed for sickle cell disease, affects the heart's electrical activity. Thirty-three healthy adults received different doses of the drug, a placebo, or an approved heart medication. The goal was to check for any heart rhythm changes before moving to larger patient studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
PAREXEL Intl - EPCU-Baltimore
Baltimore, Maryland, 21225, United States
Conditions
Explore the condition pages connected to this study.